But it helps!
Only patients with a proven needle phobia or severe problems with injection sites should get Pfizer's inhaled insulin product Exubera, Britain's cost-effectiveness watchdog, NICE, said on Wednesday.
The National Institute for Health and Clinical Excellence (NICE) had already said the treatment was not worth the money in April.
That initial decision provoked a storm of protest and Andrea Sutcliffe, deputy chief executive at NICE, said the revised guideline showed flexibility.
This means some patients would have to prove mental illness to get Exubera as under the NICE proposal, injection phobia would have to be diagnosed by a psychiatrist or psychologist.
Source: Reuters
No comments:
Post a Comment